A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TNDM SEC filings page.
Tandem Diabetes Care, Inc. (TNDM) reported $1.1B in revenue over the twelve months to Sep 30, 2026, up 6.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is growing, but overhead and balance-sheet pressure are absorbing gross-profit gains faster than cash generation can support.
Gross margin improved while operating margin fell in FY2025; SG&A grew faster than revenue, so scale was not translating into operating leverage. That divergence matters because the company is expanding its commercial cost base without producing a corresponding improvement in the cash engine; this is an operating-cost problem, not deterioration in reported gross economics.
Cash conversion weakened sharply: operating cash flow shifted from
Leverage increased: debt-to-equity rose to 2.0x in FY2025, while liabilities reached
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Tandem Diabetes Care, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Tandem Diabetes Care, Inc. scores 21/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Tandem Diabetes Care, Inc. scores 78/100 on it among other operating companies.
Tandem Diabetes Care, Inc. carried $2.00 of long-term debt for every $1 of shareholders' equity at the end of fiscal year 2025, a debt-to-equity ratio of 2.00. With no positive EBITDA in fiscal year 2025, Tandem Diabetes Care, Inc. is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 18/100 among other operating companies measured the same way.
Tandem Diabetes Care, Inc. held $2.55 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 2.55. Liquidity ranks operating companies on that ratio, and Tandem Diabetes Care, Inc. scores 72/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Tandem Diabetes Care, Inc. scores 21/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Tandem Diabetes Care, Inc. scores 19/100 on it among other operating companies.
Tandem Diabetes Care, Inc. scores -0.04, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.3B against total assets of $881.1M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Tandem Diabetes Care, Inc. passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Tandem Diabetes Care, Inc. reported a net loss of $204.7M while operations used $9.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Tandem Diabetes Care, Inc. reported an operating loss of $187.3M against $7.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Tandem Diabetes Care, Inc. generated $283.7M in revenue in Q3 2026. This represents an increase of 13.8% from the same quarter a year earlier. Against the prior quarter it is up 11.4%.
Tandem Diabetes Care, Inc.'s EBITDA was $2.1M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Tandem Diabetes Care, Inc. reported a net loss of $7.1M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Tandem Diabetes Care, Inc. earned -$0.10 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Tandem Diabetes Care, Inc. recorded an outflow of $5.5M in free cash flow in Q3 2026, representing a cash shortfall after capex. This represents a decrease of 232.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Tandem Diabetes Care, Inc. held $72.8M in cash against $603.4M in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Tandem Diabetes Care, Inc.'s gross margin was 56.5% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 2.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.3 percentage points.
Tandem Diabetes Care, Inc.'s operating margin was -0.8% in Q3 2026, reflecting core business profitability. This is up 8.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.6 percentage points.
Tandem Diabetes Care, Inc.'s net profit margin was -2.5% in Q3 2026, showing the share of revenue converted to profit. This is up 6.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.8 percentage points.
Tandem Diabetes Care, Inc.'s quarterly ROE was -5.2% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 10.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 11.0 percentage points.
Capital Allocation
Tandem Diabetes Care, Inc. invested $48.8M in research and development in Q3 2026. This represents an increase of 0.3% from the same quarter a year earlier. Against the prior quarter it is up 4.1%.
Tandem Diabetes Care, Inc. invested $4.7M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 14.5% from the same quarter a year earlier. Against the prior quarter it is up 15.7%.
Not reported for Q3 2026.
TNDM Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $283.7M+13.8% | $254.6M+5.8% | $247.2M+5.5% | $290.4M+2.7% | $249.3M+2.2% | $240.7M+8.5% | $234.4M+22.3% | $282.6M+43.6% |
| Cost of Revenue | $123.3M+7.2% | $109.8M-4.4% | $110.4M-4.8% | N/A | $115.0M-3.7% | $114.8M+5.2% | $116.0M+19.6% | N/A |
| Gross Profit | $160.4M+19.5% | $144.8M+15.0% | $136.8M+15.5% | $167.5M+6.4% | $134.3M+7.7% | $125.9M+11.6% | $118.4M+25.1% | $157.5M+68.8% |
| R&D Expenses | $48.8M+0.3% | $46.9M-2.5% | $46.0M-8.3% | N/A | $48.7M-4.7% | $48.1M-2.4% | $50.2M+8.6% | N/A |
| SG&A Expenses | $113.9M+5.1% | $111.6M+1.9% | $108.2M-5.0% | N/A | $108.4M+8.8% | $109.6M+16.3% | $113.9M+26.4% | N/A |
| Operating Income | -$2.4Mn/m | -$13.8Mn/m | -$17.4Mn/m | $8.3Mn/m | -$22.9Mn/m | -$51.8Mn/m | -$120.9Mn/m | -$581Kn/m |
| EBITDA | $2.1Mn/m | -$9.3Mn/m | -$12.9Mn/m | $12.8M+249.0% | -$18.4Mn/m | -$47.4Mn/m | -$116.6Mn/m | $3.7Mn/m |
| Interest Expense | $2.3M+11.6% | $2.5M+28.6% | $2.2M+18.4% | N/A | $2.1M+10.7% | $1.9M+6.2% | $1.9M-1.8% | N/A |
| Income Tax | -$608Kn/m | $510Kn/m | $516K-93.9% | N/A | -$4.0M-724.5% | -$5.3M-596.9% | $8.5M+165.8% | N/A |
| Net Income | -$7.1Mn/m | -$21.2Mn/m | -$20.4Mn/m | -$589K-178.0% | -$21.2Mn/m | -$52.4Mn/m | -$130.6Mn/m | $755Kn/m |
| EPS (Basic) | -$0.10n/m | -$0.31n/m | -$0.30n/m | -$0.01-200.0% | -$0.31n/m | -$0.78n/m | -$1.97n/m | $0.01n/m |
| EPS (Diluted) | -$0.10n/m | -$0.31n/m | -$0.30n/m | -$0.01-200.0% | -$0.31n/m | -$0.78n/m | -$1.97n/m | $0.01n/m |
| Diluted Shares (Avg) | 70M+3.0% | 69M+2.9% | 68M+3.0% | 68M+2.8% | 68M+3.2% | 67M+3.2% | 66M+1.7% | 66M+1.2% |
TNDM Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.2B+32.6% | $1.2B+31.8% | $1.2B+25.1% | $881.1M-8.9% | $874.7M-8.7% | $875.7M-6.6% | $922.1M-2.0% | $967.7M+1.6% |
| Current Assets | $820.7M+33.0% | $804.6M+30.9% | $887.1M+33.7% | $618.1M-14.7% | $616.9M-18.0% | $614.8M-16.2% | $663.4M-9.8% | $724.5M-3.1% |
| Cash & Equivalents | $72.8M-20.8% | $62.8M-2.0% | $179.3M+234.7% | $90.6M+30.9% | $91.9M+87.5% | $64.1M+34.4% | $53.6M-9.2% | $69.2M+17.6% |
| Short-Term Investments | $370.2M+63.0% | $393.2M+56.5% | $390.9M+24.1% | $202.0M-45.3% | $227.2M-46.5% | $251.2M-37.9% | $315.1M-22.9% | $369.1M-9.8% |
| Inventory | $143.1M+4.3% | $135.1M-5.2% | $126.4M-10.5% | $128.8M-13.9% | $137.3M-9.9% | $142.6M-11.8% | $141.2M-8.3% | $149.6M-5.3% |
| Accounts Receivable | $180.0M+42.9% | $162.1M+26.2% | $140.7M+11.1% | $165.5M+44.4% | $125.9M+17.5% | $128.4M+30.9% | $126.6M+36.1% | $114.6M+8.6% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $1.0B+38.1% | $1.0B+37.9% | $1.0B+33.1% | $725.9M+3.0% | $741.7M+3.0% | $742.5M+5.5% | $766.9M+9.9% | $704.6M+10.3% |
| Current Liabilities | $256.1M+1.4% | $253.0M+0.5% | $248.0M-14.0% | $242.7M-1.8% | $252.5M-2.6% | $251.7M+4.6% | $288.2M+49.3% | $247.0M+26.5% |
| Non-Current Liabilities | $768.3M+57.1% | $770.8M+57.1% | $773.0M+61.5% | $483.2M+5.6% | $489.1M+6.2% | $490.8M+6.0% | $478.7M-5.2% | $457.5M+3.1% |
| Long-Term Debt | $603.4M+94.9% | $602.6M+94.9% | $601.8M+94.9% | $310.0M+0.6% | $309.6M+0.6% | $309.1M+0.6% | $308.7M-11.2% | $308.3M+8.2% |
| Total Equity | $135.1M+1.6% | $130.4M-2.2% | $132.4M-14.7% | $155.2M-41.0% | $133.0M-44.1% | $133.3M-43.0% | $155.3M-36.1% | $263.1M-16.1% |
| Retained Earnings | -$1.3Bn/m | -$1.3Bn/m | -$1.3Bn/m | -$1.3Bn/m | -$1.3Bn/m | -$1.2Bn/m | -$1.2Bn/m | -$1.0Bn/m |
Not reported in any period shown, so not listed: Goodwill.
TNDM Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$819K-109.9% | -$34.6Mn/m | $11.1Mn/m | $9.8M-8.7% | $8.3M-69.1% | -$9.5Mn/m | -$18.3Mn/m | $10.7Mn/m |
| Depreciation & Amortization | $4.5M+0.4% | $4.5M+2.4% | $4.5M+4.5% | $4.5M+5.9% | $4.5M+6.7% | $4.4M+6.3% | $4.3M+6.6% | $4.2M+5.3% |
| Stock-Based Compensation | $15.9M-24.8% | $15.7M-38.6% | $15.7M-38.6% | N/A | $21.1M-19.6% | $25.6M+3.0% | $25.5M+15.7% | N/A |
| Capital Expenditures | $4.7M+14.5% | $4.0M-34.7% | $6.3M+111.4% | $6.7M+117.8% | $4.1M-21.9% | $6.2M-4.0% | $3.0M-33.5% | $3.1M-41.0% |
| Free Cash Flow | -$5.5M-232.0% | -$38.7Mn/m | $4.8Mn/m | $3.1M-59.4% | $4.2M-80.6% | -$15.7Mn/m | -$21.2Mn/m | $7.6Mn/m |
| Investing Cash Flow | $18.0M-12.4% | -$87.3M-250.2% | -$195.4M-2227.7% | -$15.0M-398.9% | $20.5Mn/m | $58.1Mn/m | $9.2Mn/m | $5.0Mn/m |
| Financing Cash Flow | -$7.0Mn/m | $2.2Mn/m | $274.2Mn/m | $2.6M+13.1% | -$1.6Mn/m | -$39.7Mn/m | -$4.7M-134.5% | $2.3M-12.0% |
| Share Buybacks | N/A | N/A | N/A | $0n/m | $0n/m | $0n/m | $0-100.0% | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
TNDM Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.5%+2.7pp | 56.9%+4.6pp | 55.3%+4.8pp | 57.7%+2.0pp | 53.9%+2.8pp | 52.3%+1.5pp | 50.5%+1.1pp | 55.7%+8.3pp |
| Operating Margin | -0.8%+8.3pp | -5.4%+16.1pp | -7.0%+44.5pp | 2.9%+3.1pp | -9.2%+1.5pp | -21.5%-7.7pp | -51.6%-29.8pp | -0.2%+17.6pp |
| Net Margin | -2.5%+6.0pp | -8.3%+13.5pp | -8.3%+47.4pp | -0.2%-0.5pp | -8.5%+1.0pp | -21.8%-7.9pp | -55.7%-33.4pp | 0.3%+15.5pp |
| Return on Equity | -5.2%+10.7pp | -16.2%+23.1pp | -15.4%+68.7pp | -0.4%-0.7pp | -15.9%-6.1pp | -39.3%-26.1pp | -84.1%-66.5pp | 0.3%+9.9pp |
| Return on Assets | -0.6%+1.8pp | -1.8%+4.1pp | -1.8%+12.4pp | -0.1%-0.1pp | -2.4%0.0pp | -6.0%-2.7pp | -14.2%-9.6pp | 0.1%+3.2pp |
| Current Ratio | 3.21+0.8x | 3.18+0.7x | 3.58+1.3x | 2.55-0.4x | 2.44-0.5x | 2.44-0.6x | 2.30-1.5x | 2.93-0.9x |
| Debt-to-Equity | 4.47+2.1x | 4.62+2.3x | 4.55+2.6x | 2.00+0.8x | 2.33+1.0x | 2.32+1.0x | 1.99+0.6x | 1.17+0.3x |
| Liabilities-to-Equity | 7.58+2.0x | 7.85+2.3x | 7.71+2.8x | 4.68+2.0x | 5.58+2.5x | 5.57+2.6x | 4.94+2.1x | 2.68+0.6x |
| Asset Turnover | 0.240.0x | 0.22-0.1x | 0.210.0x | 0.330.0x | 0.290.0x | 0.270.0x | 0.25+0.1x | 0.29+0.1x |
| FCF Margin | -1.9%-3.6pp | -15.2%-8.7pp | 1.9%+11.0pp | 1.1%-1.6pp | 1.7%-7.2pp | -6.5%-1.2pp | -9.1%-2.6pp | 2.7%+9.0pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Tandem Diabetes Care, Inc. TNDM | FY2025 | $1.0B | -$204.7M | -20.2% | $1.2B | 38/100 |
| NovoCure Limited NVCR | FY2025 | $655.4M | -$136.2M | -20.8% | $1.3B | 66/100 |
| PROCEPT BioRobotics Corporation PRCT | FY2025 | $308.1M | -$95.6M | -31.0% | $1.4B | 54/100 |
| CONMED Corporation CNMD | FY2025 | $1.4B | $47.1M | 3.4% | $1.4B | 53/100 |
| Butterfly Network, Inc. BFLY | FY2025 | $97.6M | -$77.1M | -79.0% | $1.5B | 74/100 |
| Enovis Corporation ENOV | FY2025 | $2.2B | -$1.2B | -52.7% | $1.6B | 34/100 |
Where Tandem Diabetes Care, Inc. Ranks
Frequently Asked Questions
Tandem Diabetes Care, Inc. (TNDM) reported $1.0B in total revenue for fiscal year 2025. This represents a 7.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Tandem Diabetes Care, Inc. (TNDM) revenue grew by 7.9% year-over-year, from $940.2M to $1.0B in fiscal year 2025.
No, Tandem Diabetes Care, Inc. (TNDM) reported a net loss of $49.2M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $204.7M, with a net profit margin of -20.2%.
Tandem Diabetes Care, Inc. (TNDM) had EBITDA of -$169.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Tandem Diabetes Care, Inc. (TNDM) had $90.6M in cash and equivalents against $310.0M in long-term debt.
Tandem Diabetes Care, Inc. (TNDM) had a gross margin of 53.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Tandem Diabetes Care, Inc. (TNDM) had an operating margin of -18.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Tandem Diabetes Care, Inc. (TNDM) had a net profit margin of -20.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Tandem Diabetes Care, Inc. (TNDM) has a return on equity of -131.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Tandem Diabetes Care, Inc. (TNDM) recorded an outflow of $29.7M in free cash flow during fiscal year 2025. This represents a -694.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Tandem Diabetes Care, Inc. (TNDM) recorded an outflow of $9.7M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Tandem Diabetes Care, Inc. (TNDM) had $881.1M in total assets as of fiscal year 2025, including both current and long-term assets.
Tandem Diabetes Care, Inc. (TNDM) invested $19.9M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Tandem Diabetes Care, Inc. (TNDM) invested $193.1M in research and development during fiscal year 2025.
Tandem Diabetes Care, Inc. (TNDM) had a current ratio of 2.55 as of fiscal year 2025, which is generally considered healthy.
Tandem Diabetes Care, Inc. (TNDM) had a debt-to-equity ratio of 2.00 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Tandem Diabetes Care, Inc. (TNDM) had a liabilities-to-equity ratio of 4.68 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Tandem Diabetes Care, Inc. (TNDM) had a return on assets of -23.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Tandem Diabetes Care, Inc. (TNDM) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $1.2B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Tandem Diabetes Care, Inc. (TNDM) trades at 1.1x sales, its market capitalization divided by $1.1B revenue, trailing 12 months to September 30, 2026. The market capitalization is $1.2B as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Tandem Diabetes Care, Inc. (TNDM) has an Altman Z-Score of -0.04, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Tandem Diabetes Care, Inc. (TNDM) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Tandem Diabetes Care, Inc. (TNDM) reported a net loss of $204.7M while operations used $9.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Tandem Diabetes Care, Inc. (TNDM) reported an operating loss of $187.3M against $7.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Tandem Diabetes Care, Inc. (TNDM) scores 38 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.